Skip to main content
Clinical Trials/CTRI/2018/03/012373
CTRI/2018/03/012373
Completed
Phase 4

A Phase 4 clinical trial to evaluate safety and efficacy of Velseal to achieve Haemostasis in traumatic or surgical wound, both Venous and arterial bleeds. - VELSEA

Datt Mediproducts Pvt Ltd0 sites101 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: T888- Other specified complications of surgical and medical care, not elsewhere classifiedHealth Condition 2: null- Patients who require haemostasis control for traumatic injuries, both venous and arterial bleeds.
Sponsor
Datt Mediproducts Pvt Ltd
Enrollment
101
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
September 7, 2016
Last Updated
4 years ago
Study Type
Pms

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Males and females above 18 years of age who require haemostasis control for traumatic injuries, both venous and arterial bleeds.
  • 2\. Subjects who can provide informed consent form in writing and medically in a position to undergo consent and screening processes.
  • 3\. The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow\-up evaluations.

Exclusion Criteria

  • 1\. Subjects who present with medical emergency, where treatment is more priority than the informed consent process.
  • 2\. Subjects who cannot provide informed consent such as unconscious subjects.
  • 3\. The subjects who have been treated with other higher treatment for Haemorrhage control such as Tourniquets for more than 2 hours, Blood or platelet\-rich\-plasma transfusion etc.
  • 4\. Subjects with haematocrit less than 38% or haemoglobin less than 10 gm%.
  • 5\. Subjects with known haemorrhagic disorders like GI bleeding, Ante partum haemorrhage, metropathia haemorrhagica, history of haematemesis, haematuria, epistaxis etc.
  • 6\. Known cases of genetic bleeding disorder.
  • 7\. Subjects who have platelet count one thousand or more below the lower normal limit.
  • 8\. Subjects with known possible loss of plasma or blood from other areas than wound such as lacerations, uterine bleeding, gastro\-intestinal bleeding etc.
  • 9\. The subject has an active infection at the surgical site.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 4
A study to evaluate safety and effectiveness of Apremilast drug in patients suffering from a disease of stiff and swollen joints (arthritis) along with disease of skin (psoriasis)Health Condition 1: L405- Arthropathic psoriasis
CTRI/2019/01/017122Glenmark Pharmaceuticals Ltd
Active, not recruiting
Phase 4
To compare combination of study with marketed other combination of drug in patients having both anxiety and depression.Health Condition 1: F418- Other specified anxiety disorders
CTRI/2022/11/047050Mankind Pharma Limited
Recruiting
Not Applicable
Trial to evaluate efficacy and safety of modified new drug of Pranlukast(Prakanon), compared with Pranlukast (Onon®)Diseases of th respiratory system
KCT0000457Ewha Womans University Medical Center40
Active, not recruiting
Phase 1
Study to assess the efficacy and safety of a basal insulin (Glargine 300) on glycemic control type 2 diabetic patients during hospitalization and at discharge.Type 2 DiabetesMedDRA version: 18.1Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2015-004715-20-ESSANOFI-AVENTIS, S.A.106
Not yet recruiting
Phase 4
Phase IV clinical study on the safety and effectiveness of Sanqi Longxuejie Capsules in the treatment of coronary heart disease with stable exertional angina pectoris (Grade I, II)
ITMCTR2100005341Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences